




EY Entrepreneur
of the year-2013



FROST & SULLIVAN
Best Practices-2013



Business today/YES bank
Excellence Awards-2013

Eris
Eris Lifesciences Ltd.

Date: August 17, 2017

To The Department of Corporate Services BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001 Security Code: 540596	To National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051 Symbol: ERIS
---	--

SUBJECT: OUTCOME OF THE BOARD MEETING HELD TODAY, i.e. AUGUST 17, 2017

Dear Sir/Madam,

The Board of Directors of the Company at their meeting held today i.e. August 17, 2017 duly approved and took on record the limited reviewed Unaudited Standalone Financial Results and the limited reviewed Unaudited Consolidated Financial Results for the quarter/Three months ended June 30, 2017.

Please find enclosed herewith Standalone and Consolidated Financial Results for the quarter ended June 30, 2017 along with the Limited Review Reports of the Auditors.

The meeting of the Board of Directors commenced at 1:30 pm and concluded at 2:40 pm.

This is for your information and record.

Thanking You


For Eris Lifesciences Limited

Milind Talegaonkar
Company Secretary & Compliance Officer
Mem. No. A26493

Encl: a/a

Registered Office:

8th Floor, Commerce House - IV, Nr. Prahlad Nagar Garden, 100 Ft. Road, Ahmedabad - 380 015, Gujarat, India
Phone: +91 - 79 - 30451111 / 30179400 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in
CIN: L24232GJ2007PLC049867




Eris
Eris Lifesciences Ltd.

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2017

[Rs. in Million except per share data]

Particulars	For Quarter Ended	
	June 30, 2017 (Unaudited)	June 30, 2016 (Refer Note-6)
Revenue from Operations	1,622.56	1,844.34
Other Income	70.95	51.36
Total Income	1,693.51	1,895.70
Expenses		
Cost of materials consumed	113.85	68.37
Purchase of stock-in-trade	82.80	178.25
Changes in Inventories of Finished goods, Work-in-Progress and Stock-in-trade	7.95	122.94
Employee Benefits Expense	298.74	306.91
Finance Costs	-	0.33
Depreciation & Amortisation Expense	39.11	45.23
Other Expenses	428.31	455.46
Total Expenses	970.76	1,177.49
Profit before Tax	722.75	718.21
Tax Expense		
Current Tax	24.83	108.31
Deferred Tax	(1.55)	(11.81)
Total Tax Expense	23.28	96.50
Net Profit for the period	699.47	621.71
Other Comprehensive Income	(1.23)	(1.23)
Items that will not be reclassified to profit or loss	(1.88)	(1.88)
Income tax relating to items that will not be reclassified to profit or loss	0.65	0.65
Total Comprehensive Income	698.24	620.48
Paid Up Equity Share Capital (Face Value of Rs.1 each)	137.50	137.50
Earnings Per Share (of Rs. 1 each) (not annualised for the quarter) :		
Basic	5.09	4.52
Diluted	5.09	4.52
See accompanying notes to the financial results		



Registered Office:

6th, 7th & 8th Floor, Commerce House - IV, Nr. Prahlad Nagar Garden, 100 Ft. Road, Ahmedabad - 380 015, Gujarat, India
 Phone: +91 - 79 - 30451111 / 30179400 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in
 CIN: L24232GJ2007PLC049867


Notes :

- 1 The above statement of financial results ("the Statement") of the Company were reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on August 17, 2017. The Statutory Auditors of the Company have carried out Limited Review of the Statement.
- 2 During the quarter ended on June 30, 2017, the Company has completed the Initial Public Offer ('IPO') through Offer for Sales (OFS).

The Company was listed on June 29, 2017 and the Statement has been drawn for the first time in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (The "Listing Obligations"). Since the results for the quarter ended June 30, 2016 were not presented under the Indian GAAP ("Previous GAAP"), the reconciliation of Profit / Loss under Previous GAAP to Total Comprehensive Income under Ind AS is not presented.
- 3 These financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and in terms of Listing Regulations, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. The Company has opted to avail the relaxation provided by Securities and Exchange Board of India ('SEBI') in respect of disclosure requirements of corresponding figures for the earlier periods.
- 4 The company is primarily engaged in one business segment namely pharmaceuticals as determined by the chief operating decision maker in accordance with Ind AS 108 - "Operating Segment".
- 5 The Company has introduced 'Eris Lifesciences Employee Stock Option Plan 2017' ("ESOP 2017" / "Plan") through the resolution passed by the Board of Directors on 2nd February, 2017 and the same was approved by the shareholders at the extra ordinary general meeting held on 3rd February, 2017. Under the scheme, 391,599 (Three lakhs ninety one thousand five hundred ninety nine only) equity shares have been granted to eligible employees of the company and each option (after it is vested) is exercisable for one equity share having face value of Rs. 1 each for an exercise price of Rs. 451. Vesting of the options shall take place over a maximum period of 5 years with a minimum vesting period of 1 year from the date of grant i.e. 12th April, 2017. The exercise period would be a maximum of 5 years from the date of vesting of options.
- 6 The financial results for the quarter ended June 30, 2016 have not been reviewed by the statutory auditors and has been presented based on the information compiled by the management after making necessary adjustment to give a true and fair view of the results in accordance with Ind AS.



Place: Ahmedabad
Date: August 17, 2017



For Eris Lifesciences Limited

Amit Bakshi
Chairman and Managing Director
DIN : 01250925

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF
ERIS LIFESCIENCES LIMITED
(Formerly Known as Eris Lifesciences Private Limited)

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **ERIS LIFESCIENCES LIMITED** ("the Company"), for the Quarter ended June 30, 2017 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

As stated in Note 6 of the Statement, we have not performed a review or audit of the figures relating to the corresponding quarter ended June 30, 2016.

2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.



3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For DELOITTE HASKINS & SELLS LLP
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)




Kartikaya Raval

Kartikaya Raval
Partner

(Membership No. 106189)

Ahmedabad, August 17, 2017



STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2017

[Rs. In Million except per share data]

Particulars	For Quarter Ended	
	June 30, 2017 (Unaudited)	June 30, 2016 (Refer Note-7)
Revenue from Operations	1,852.07	1,824.23
Other Income	68.67	51.54
Total Income	1,920.74	1,875.77
Expenses		
Cost of materials consumed	113.85	116.24
Purchase of stock-in-trade	126.49	92.45
Changes in Inventories of Finished goods, Work-in-Progress and Stock-in-trade	34.24	100.57
Employee Benefits Expense	356.50	314.05
Finance Costs	0.15	0.33
Depreciation and Amortisation Expense	46.24	54.10
Other Expenses	506.62	465.00
Total Expenses	1,184.09	1,142.74
Profit before Tax	736.65	733.03
Tax Expense		
Current Tax	24.83	113.98
Deferred Tax	3.45	(8.52)
Total Tax Expense	28.28	105.46
Net Profit for the period	708.37	627.57
Attributable to :		
- Owners of the company	708.37	624.39
- Non controlling interest	-	3.18
Other Comprehensive Income	(1.21)	(1.23)
Items that will not be reclassified to profit or loss	(1.86)	(1.88)
Income tax relating to items that will not be reclassified to profit or loss	0.65	0.65
Total Comprehensive Income	707.16	626.34
Attributable to :		
- Owners of the company	707.16	623.16
- Non controlling interest	-	3.18
Paid Up Equity Share Capital (Face Value of Rs.1 each)	137.50	137.50
Earnings Per Share (of Rs. 1 each) (not annualised for the quarter) :		
Basic	5.15	4.56
Diluted	5.15	4.56
See accompanying notes to the financial results		



Registered Office:

6th, 7th & 8th Floor, Commerce House - IV, Nr. Prahlad Nagar Garden, 100 Ft. Road, Ahmedabad - 380 015, Gujarat, India
 Phone: +91 - 79 - 30451111 / 30179400 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in
 CIN: L24232GJ2007PLC049867

Notes :

1 The above statement of financial results ("the Statement") of the Group were reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on August 17, 2017. The Statutory Auditors of the Company have carried out Limited Review of the Statement.

2 Information of Standalone Unaudited Financial Result of the Company is as Under:

Particulars	Quarter Ended	
	June 30, 2017 (Unaudited)	June 30, 2016 (Refer Note -7)
Revenue from Operations	1,622.56	1,844.34
Profit Before Tax	722.75	718.21
Profit after Tax	699.47	621.71

3 During the quarter ended on June 30, 2017, the Company has completed the Initial Public Offer ('IPO') through Offer for Sales (OFS).

The Company was listed on June 29, 2017 and the Statement has been drawn for the first time in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (The "Listing Obligations"). Since the results for the quarter ended June 30, 2016 were not presented under the Indian GAAP ("Previous GAAP"), the reconciliation of Profit / Loss under Previous GAAP to Total Comprehensive Income under Ind AS is not presented.

4 These financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and in terms of Listing Regulations, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. The Company has opted to avail the relaxation provided by Securities and Exchange Board of India ('SEBI') in respect of disclosure requirements of corresponding figures for the earlier periods.

5 The group is primarily engaged in one business segment namely pharmaceuticals as determined by the chief operating decision maker in accordance with Ind AS 108 - "Operating Segment".

6 The Company has introduced 'Eris Lifesciences Employee Stock Option Plan 2017' ("ESOP 2017"/ "Plan") through the resolution passed by the Board of Directors on 2nd February, 2017 and the same was approved by the shareholders at the extra ordinary general meeting held on 3rd February, 2017. Under the scheme, 391,599 (Three lakhs ninety one thousand five hundred ninety nine only) equity shares have been granted to eligible employees of the company and each option (after it is vested) is exercisable for one equity share having face value of Rs. 1 each for an exercise price of Rs. 451. Vesting of the options shall take place over a maximum period of 5 years with a minimum vesting period of 1 year from the date of grant i.e. 12th April, 2017. The exercise period would be a maximum of 5 years from the date of vesting of options.

7 The financial results for the quarter ended June 30, 2016 have not been reviewed by the statutory auditors and has been presented based on the information compiled by the management after making necessary adjustment to give a true and fair view of the results in accordance with Ind AS.



Place: Ahmedabad
Date : August 17, 2017



For Eris Lifesciences Limited

Amlit Bakshi
Chairman and Managing Director
DIN : 01250925

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF ERIS LIFESCIENCES LIMITED (Formerly Known as Eris Lifesciences Private Limited)

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **ERIS LIFESCIENCES LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the Quarter ended June 30, 2017 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement, which is the responsibility of the Parent's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

As stated in Note 7 of the Statement, we have not performed a review or audit of the figures relating to the corresponding quarter ended June 30, 2016.

2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Parent's personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. The Statement includes the results of the following entities:
 - i. Eris Lifesciences Limited (Parent)
 - ii. Aprica Healthcare Private Limited (Subsidiary)
 - iii. Kinedex Healthcare Private Limited (Subsidiary)
 - iv. Eris Therapeutics Private Limited (Subsidiary)



4. Based on our review conducted as stated above and based on the consideration of the review reports of the other auditors referred to in paragraph 5 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. We did not review the financial results of 3 subsidiaries included in the consolidated unaudited financial results, whose interim financial results reflect total revenues of Rs. 230.82 million for the Quarter ended June 30, 2017, and total profit after tax of Rs. 14 million and Total comprehensive income of Rs. 14.02 million for the Quarter ended June 30, 2017, as considered in the consolidated unaudited financial results. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our report on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the other auditors.

Our report on the Statement is not modified in respect of these matters.

For DELOITTE HASKINS & SELLS LLP
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



Kartikya Raval

Kartikya Raval
Partner
(Membership No. 106189)

Ahmedabad, August, 17, 2017